Pulmonary adrenomedullin counteracts deterioration of coronary flow and myocardial performance evoked by pulmonary endothelins in experimental acute respiratory distress syndrome
- 1 May 2001
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 29 (5) , 1027-1032
- https://doi.org/10.1097/00003246-200105000-00031
Abstract
We recently showed that pulmonary endothelins may affect coronary circulation under various experimental and clinical conditions. Here, we investigated the effect of pulmonary mediators on coronary tone in experimental acute respiratory distress syndrome. We focused particularly on pulmonary endothelin-1, a major vasoconstrictor in acute respiratory distress syndrome, and on adrenomedullin, a potent vasodilator that is up-regulated by inflammatory stimuli. Controlled experiment that used isolated organs. Experimental laboratory. Wistar rats. The saline effluent from an isolated lung was used to serially perfuse the coronary vessels of an isolated heart. We compared serial perfusion after 2-hr pretreatment of lungs with vehicle or endotoxin (50 microg/mL), and we used the following drugs to elucidate the coronary response observed: the endothelin type A receptor antagonist BQ-123 (2 microM), the endothelin type B antagonist A-192621 (500 nM), the endothelin-converting enzyme inhibitor phosphoramidon (50 microM), the calcitonin gene-related peptide type-1 receptor antagonist hCGRP(8-37) (2 microM), and the adrenomedullin receptor antagonist hAM(22-52) (200 nM) (n = 6 each). In controls, serial perfusion decreased coronary flow to 87 +/- 3% of baseline (p < .05). BQ-123 and phosphoramidon prevented this effect, whereas blockade of endothelin type B and adrenomedullin-binding receptors had no effect. After endotoxin challenge, coronary flow significantly increased to 110 +/- 2%. This response was augmented by BQ-123 (124 +/- 2%) and phosphoramidon (123 +/- 3%); A-192621 had no effect. Application of hCGRP(8-37) and hAM(22-52) significantly decreased coronary flow to 81 +/- 3% and 88 +/- 2%, respectively. Flow decrease after blockade of both adrenomedullin-binding receptors (73 +/- 2%) significantly deteriorated peak left ventricular pressure, to 82 +/- 6% of baseline; rate of pressure increase, to 81 +/- 5%; and rate of pressure decline, to 77 +/- 6%. Endotoxin pretreatment elevated pulmonary venous big endothelin-1 (three-fold), endothelin-1 (two-fold), and adrenomedullin (five-fold). In experimental acute respiratory distress syndrome, pulmonary adrenomedullin--via calcitonin gene-related peptide type-1 receptor and adrenomedullin receptor--outweighs the coronary vasoconstrictor impact of pulmonary big endothelin-1 exerted via endothelin type A receptors after conversion to mature endothelin-1. The consequence is prevention of flow-related deterioration of myocardial performance.Keywords
This publication has 37 references indexed in Scilit:
- Pulmonary Release and Coronary and Peripheral Consumption of Big Endothelin and Endothelin-1 in Severe Heart FailureCirculation, 2000
- Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunctionCritical Care Medicine, 1998
- Role of Endothelin in Endotoxin-induced Sustained Pulmonary Hypertension in SheepAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Pulmonary Big Endothelin Affects Coronary Tone and Leads to Enhanced, ET A -Mediated Coronary Constriction in Early Endothelial DysfunctionCirculation, 1997
- Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1Circulation, 1996
- Endotoxin Markedly Elevates Plasma Concentration and Gene Transcription of Adrenomedullin in RatBiochemical and Biophysical Research Communications, 1995
- Expression of adrenomedullin in normal human lung and in pulmonary tumors.Endocrinology, 1995
- Role of atrial natriuretic factor in lung physiology and pathology.American Journal of Respiratory and Critical Care Medicine, 1995
- Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits.Proceedings of the National Academy of Sciences, 1992
- Increased pulmonary vascular resistance and permebility due to arachidonate metabolism in isolated rabbit lungsProstaglandins, 1982